6533b828fe1ef96bd12879f2

RESEARCH PRODUCT

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Daniele SantiniGiovanni GrignaniMassimo AgliettaBruno VincenziGiuseppe ToniniAntonio RussoGiuseppe BadalamentiMariella Spalato CerusoAndrea NapolitanoFrancesco Pantano

subject

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab

description

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

yearjournalcountryeditionlanguage
2017-01-01
10.1016/j.critrevonc.2017.06.006http://hdl.handle.net/2318/1652492